Kaleb Bogale1, Kent Vrana2, Wesley Raup- Konsavage2, Vonn Walter3,4, August Stuart5, Shannon Dalessio5, Walter Koltun6, Nana Bernasko5, Andrew Tinsley5, Emmanuelle Williams5, Kofi Clarke5, Matthew D Coates2,5. 1. Department of Medicine, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA. 2. Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA. 3. Department of Public Health Sciences, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA. 4. Department of Biochemistry, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA. 5. Department of Medicine, Division of Gastroenterology & Hepatology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA. 6. Department of Surgery, Division of Colorectal Surgery, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA.
Abstract
OBJECTIVES: We aimed to evaluate the incidence, predisposing factors and impacts of polysubstance use (PSU) (ie, the concurrent use or abuse of two or more drugs or substances) in inflammatory bowel disease (IBD). METHODS: Data of patients enrolled between 1 January 2015 and 31 August 2019 from a single tertiary care referral center were retrospectively collected. Patients' baseline and clinical characteristics and their antidepressant and/or anxiolytic medications were abstracted. Associations between PSU and patients' characteristics were analyzed. Multivariate logistic regression models were fit, incorporating significant clinical factors. RESULTS: Altogether 315 patients with IBD (166 women, 149 men; 214 with Crohn's disease and 101 ulcerative colitis) were enrolled. Of them, 66 (21.0%) exhibited PSU (CD 21.5%, UC 19.8%); 37.5% had moderate to severe disease activity, 34.3% with extraintestinal manifestations (EIM), 41.6% with an anxious or depressed state and 69.8% had used healthcare resources in the prior 12 months. Moreover, 71.2% used two substances, while 27.3% used three substances. In the total cohort, EIM (odds ratio [OR] 1.97, 95% confidence interval [CI] 1.14-3.34, P = 0.019) and antidepressant or anxiolytic use (OR 2.51, 95% CI 1.45-4.39, P < 0.001) were positively associated with PSU on multivariate analysis. PSU was associated with increased rate of IBD-associated imaging (57.6% vs 47.0%, P < 0.05). CONCLUSIONS: PSU is common in IBD. EIM, antidepressant and/or anxiolytic use and imaging studies were independently associated with PSU. This study reinforces the importance of screening patients with IBD for substance use, particularly those with EIM and using antidepressants and/or anxiolytics.
OBJECTIVES: We aimed to evaluate the incidence, predisposing factors and impacts of polysubstance use (PSU) (ie, the concurrent use or abuse of two or more drugs or substances) in inflammatory bowel disease (IBD). METHODS: Data of patients enrolled between 1 January 2015 and 31 August 2019 from a single tertiary care referral center were retrospectively collected. Patients' baseline and clinical characteristics and their antidepressant and/or anxiolytic medications were abstracted. Associations between PSU and patients' characteristics were analyzed. Multivariate logistic regression models were fit, incorporating significant clinical factors. RESULTS: Altogether 315 patients with IBD (166 women, 149 men; 214 with Crohn's disease and 101 ulcerative colitis) were enrolled. Of them, 66 (21.0%) exhibited PSU (CD 21.5%, UC 19.8%); 37.5% had moderate to severe disease activity, 34.3% with extraintestinal manifestations (EIM), 41.6% with an anxious or depressed state and 69.8% had used healthcare resources in the prior 12 months. Moreover, 71.2% used two substances, while 27.3% used three substances. In the total cohort, EIM (odds ratio [OR] 1.97, 95% confidence interval [CI] 1.14-3.34, P = 0.019) and antidepressant or anxiolytic use (OR 2.51, 95% CI 1.45-4.39, P < 0.001) were positively associated with PSU on multivariate analysis. PSU was associated with increased rate of IBD-associated imaging (57.6% vs 47.0%, P < 0.05). CONCLUSIONS: PSU is common in IBD. EIM, antidepressant and/or anxiolytic use and imaging studies were independently associated with PSU. This study reinforces the importance of screening patients with IBD for substance use, particularly those with EIM and using antidepressants and/or anxiolytics.
Authors: Johanna Haapamäki; Risto P Roine; Ulla Turunen; Martti A Färkkilä; Perttu E T Arkkila Journal: J Crohns Colitis Date: 2010-10-30 Impact factor: 9.071
Authors: Karen A Hanson; Edward V Loftus; W Scott Harmsen; Nancy N Diehl; Alan R Zinsmeister; William J Sandborn Journal: Inflamm Bowel Dis Date: 2009-05 Impact factor: 5.325
Authors: Timna Naftali; Lihi Bar Lev; Doron Yablecovitch; Doron Yablekovitz; Elisabeth Half; Fred M Konikoff Journal: Isr Med Assoc J Date: 2011-08 Impact factor: 0.892
Authors: Aaron B Cohen; Dale Lee; Millie D Long; Michael D Kappelman; Christopher F Martin; Robert S Sandler; James D Lewis Journal: Dig Dis Sci Date: 2012-08-26 Impact factor: 3.199